Athenex Pharmaceutical Division, an Athenex, Inc. Company, Launches Levothyroxine Sodium for Injection

BUFFALO, N.Y., Dec. 26, 2018 (GLOBE NEWSWIRE) -- Athenex, Inc. (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer, today announced the launch of Levothyroxine Sodium for Injection through its subsidiary Athenex Pharmaceutical Division (APD).  The APD product was brought to market in close cooperation with Princeton, NJ-based development partner, MAIA Pharmaceuticals.  

APD is focused on supplying the US hospital market with high-quality specialty injectable products that address unmet or underserved hospital needs, including high-volume, niche and/or shortage products.

Levothyroxine Sodium for Injection products available to order from Athenex include:

  • 100 mcg per vial
  • 200 mcg per vial
  • 500 mcg per vial

Per IQVIA sales data, the Levothyroxine Sodium for Injection market in the United States exceeds $85 million annually. 

Jeffrey Yordon, Athenex’s Chief Operating Officer and President of APD, commented, “We are delighted to introduce multiple SKUs of Levothyroxine Sodium Injection to the US hospital market. Our launch of Levothyroxine demonstrates the unique ability of Athenex to work quickly and collaboratively to bring needed products to our customers. We’d like to thank our partners at MAIA for matching our agility, enabling our speed to market and supporting our unwavering commitment to delivering high-quality products that can help address our customers’ ongoing needs.”

Bikram Malik, MAIA, added, “We are thrilled with the FDA approval of MAIA’s third product and are honored to work with a seasoned and exceptional team at Athenex to bring Levothyroxine Sodium for Injection to the US market leveraging their unique cross-functional capabilities across both specialty and generic medicines. They are the best in the business. Levothyroxine is the first of what we hope to be many future product collaborations with Athenex.”

Athenex’s products emphasize quality and can help to enhance patient safety. Athenex’s AccuraSEE℠ Packaging and Labeling, a proprietary, patent-pending and highly differentiated approach to product packaging and labeling, features a unique label design for every product to give caregivers accurate information and help to reduce the risk of medication errors.

The APD product portfolio is available at

About Athenex, Inc.
Founded in 2003, Athenex, Inc. is a global clinical stage biopharmaceutical company dedicated to becoming a leader in the discovery and development of next generation drugs for the treatment of cancer. Athenex is organized around three platforms, including an Oncology Innovation Platform, a Commercial Platform and a Global Supply Chain Platform. The Company’s current clinical pipeline is derived from four different platform technologies: (1) Orascovery, based on non-absorbed P-glycoprotein inhibitor, (2) Src kinase inhibition, (3) T-cell receptor-engineered T-cells (TCR-T), and (4) Arginine deprivation therapy. Athenex’s employees worldwide are dedicated to improving the lives of cancer patients by creating more active and tolerable treatments.  Athenex has offices in Buffalo and Clarence, New York; Cranford, New Jersey; Houston, Texas; Chicago, Illinois; Hong Kong; Taipei, Taiwan; and multiple locations in Chongqing, China. For more information, please visit

About MAIA Pharmaceuticals, Inc.
Founded in 2013, MAIA is a Princeton, NJ-based specialty pharmaceutical company committed to developing, manufacturing and commercializing hospital products where there are unaddressed patient and/or practitioner needs.

Forward-Looking Statement
Except for historical information, all of the statements, expectations, and assumptions contained in this press release are forward-looking statements. These forward-looking statements are typically identified by terms such as “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “foresee,” “guidance,” “intend,” “likely,” “may,” “plan,” “potential,” “predict,” “probable,” “project,” “seek,” “should,” “will,” and similar expressions.  Actual results might differ materially from those explicit or implicit in the forward-looking statements. Important factors that could cause actual results to differ materially include: the development stage of our primary clinical candidates and related risks involved in drug development, clinical trials, regulation, manufacturing and commercialization; our reliance on third parties for success in certain areas of Athenex’s business; our history of operating losses and need to raise additional capital to continue as a going concern; competition; intellectual property risks; risks relating to doing business in China; and the other risk factors set forth from time to time in our SEC filings, copies of which are available for free in the Investor Relations section of our website at or upon request from our Investor Relations Department. All information provided in this release is as of the date hereof and we assume no obligation and do not intend to update these forward-looking statements, except as required by law.

Investor Relations:
Tim McCarthy
Managing Director, LifeSci Advisors, LLC
Tel: +1 716-427-2952 
Direct: +1 212-915-2564

Athenex, Inc.:
Randoll Sze
Chief Financial Officer

Jacqueline Li
Corporate Development and Investor Relations